UltraGreen.ai Launches US$400 Million IPO on SGX Mainboard to Fund Asia Expansion
Surgical technology company UltraGreen.ai announced a significant step in its corporate growth strategy with the launch of its initial public offering (IPO) on the mainboard of the Singapore Exchange (SGX) on November 26.
This move is designed to raise approximately US$400 million in total capital, drawing funds from both the public offering and substantial cornerstone commitments.
The firm, which utilizes advanced fluorescence imaging solutions to develop precision surgery technology, is strategically building an AI-powered platform designed to significantly aid decision-making processes during complex surgical procedures.
The company is offering over 112 million shares to the public at a price of US$1.45 per share, which is expected to raise US$162.5 million.
Complementing this, the IPO has secured firm commitments amounting to US$237.5 million from a syndicate of 16 cornerstone investors, signaling strong institutional confidence in the firm’s Business model and future growth trajectory.
The shares being offered comprise around 106.2 million placement shares targeted at institutional and other sophisticated investors through an international placement, alongside 5.9 million shares made available via a public offer in Singapore.
UltraGreen.ai shares are expected to be traded in US dollars, reflecting its international operations and investor base.
The gross proceeds accruing directly to the company from this offering are anticipated to be around US$150 million, providing a solid financial foundation for its planned global expansion.
The public offer in Singapore is slated to open on November 26 and close on December 1, with the company aiming for a trading debut on December 3, marking its official entry into the Finance markets of Asia.
Leveraging Flagship Technology and AI for Enhanced Surgical Precision
The foundation of UltraGreen.ai’s commercial success rests upon its highly specialized product portfolio, led by a flagship indocyanine green dye.
This compound serves as a crucial fluorescence agent utilized in various surgical procedures, enabling surgeons to visualize blood flow, lymphatic structures, and cancerous tissues with enhanced precision.
This advanced visualization technology is instrumental in reducing critical risks such as sepsis and is proven to significantly improve overall patient outcomes and recovery rates.
The global reach and market acceptance of the firm’s technology are evident in its sales figures, with its indocyanine green dye products having been successfully sold in 54 countries between 2022 and the first half of 2025.
Furthermore, the company boasts a long track record, having shipped 5.3 million vials of its product for surgical use since 2015, establishing a significant installed base globally.
Beyond its core dye products, UltraGreen.ai also offers other key technological components for its ecosystem, including a specialized hand-held near-infrared digital camera designed for use in fluorescence-guided surgeries.
Crucially, the firm also provides a proprietary data platform that integrates AI-based software to assist with real-time decision-making during these highly sensitive procedures.
The company intends to strategically allocate the proceeds from its Investment into further developing and enhancing its core product suite, encompassing the dye, the camera systems, and the underlying AI data platform.
Furthermore, the capital will support research into other related fluorescence-guided surgery technologies and fuel ambitious expansion plans into new markets across the Asia-Pacific, Europe, the Middle East and Africa, ensuring the firm captures the next wave of global Economy growth in surgical technology.
Strategic SGX Listing Fuels Profitability and Global Expansion Goals
UltraGreen.ai’s decision to launch its IPO on the SGX is a highly strategic one, rooted in both the company’s strong financial performance and Singapore’s unique position as a global Finance hub.
The company demonstrated impressive growth in its 2024 financial year, reporting a substantial revenue of US$114.7 million, marking a 59.3 per cent year-on-year increase.
Profitability was equally robust, with net profit reaching US$56 million, a significant jump from US$33 million the preceding year.
CEO Ravinder Sajwan emphasized that the company has already built a “profitable and scalable Business across Europe and North America” and is now expanding strategically from Singapore to tap into the substantial growth potential across Asia.
The firm is focused on creating a new category of surgical intelligence aimed at transforming global procedures.
Chairman Kwa Chong Seng explained the choice of SGX by citing Singapore’s robust protection for intellectual property and its geographical position at the crossroads of East and West, offering exceptional port connectivity and trade links to access markets on both sides of the world.
While the company’s anticipated market capitalization of around US$1.6 billion makes it currently too small for an immediate Nasdaq listing, the potential for a dual-listing via the recently announced SGX-Nasdaq bridge provides a clear future pathway for global visibility.
Mr. Sajwan also noted that being in the high-growth healthcare sector with strong profit margins makes it an ideal time to execute the Investment and begin geographical expansion, allowing the firm to put its “foot in the door” for rapid scaling across the Asian Economy.
Financial Analyst Commentary: Capitalizing on the AI-Surgery Convergence
The UltraGreen.ai IPO on the SGX is less about traditional MedTech growth and more about capitalizing on the high-margin convergence of AI and precision surgery, a critical differentiator in the Finance markets.
The strong cornerstone commitment, amounting to nearly 60% of the total raise, significantly de-risks the offering and suggests institutional validation of the firm’s technology and Business model, particularly the scalability of the indocyanine green dye combined with the future recurring revenue potential of the AI data platform.
The firm’s high-growth and impressive 2024 net profit margin (approximately 48.8%) place it firmly in a high-value category, justifying the IPO timing.
The strategic choice of Singapore for the listing directly addresses future Economy expansion in Asia-Pacific, a region where surgical procedural volumes are skyrocketing due to aging populations and rising healthcare access.
By using the SGX as a launchpad, the company mitigates the regulatory complexity of a US primary listing while maintaining international visibility and setting the stage for future expansion into the larger, more liquid Nasdaq market.
The proceeds are essential CapEx to solidify the AI platform, ensuring the firm maintains its first-mover advantage in defining the “surgical intelligence” category before larger MedTech incumbents can replicate the combined dye-imaging-AI ecosystem.
Regional Market Impact: SGX’s Enhanced Tech Pipeline and ASEAN Healthcare Disruption
The successful listing of a high-growth, profitable MedTech firm like UltraGreen.ai serves as a potent signal that the SGX is achieving its goal of diversifying its listing base beyond traditional property and REITs, significantly enhancing its profile as a platform for global Technology and Healthcare Investment.
This IPO, strategically executed in US dollars, boosts the liquidity and international relevance of the Singaporean Finance market, challenging other regional exchanges by demonstrating a viable gateway for high-quality, high-margin international Businesses looking to penetrate the Asian Economy.
For the broader ASEAN region, UltraGreen.ai’s expansion directly impacts the quality and cost of advanced healthcare.
The adoption of their fluorescence imaging solutions and AI platform will introduce a higher standard of surgical precision, accelerating the technological leapfrog in healthcare systems across Indonesia, Malaysia, and the Philippines, where capital expenditure on medical equipment is rapidly rising.
The potential to reduce complications and sepsis risks, a core product benefit, translates directly into lower overall healthcare costs and improved patient throughput—a critical Economy factor for rapidly growing, yet strained, public and private hospital systems in Southeast Asia.
This listing not only validates Singapore’s role as the regional MedTech hub but also sets a precedent for other global high-tech firms to utilize the SGX-Nasdaq bridge, solidifying Singapore’s position as the primary financial access point to the burgeoning, multi-trillion-dollar Asian healthcare Investment market.
